NASDAQ:ONC

BeOne Medicines Q1 2026 Earnings Report

BeOne Medicines logo
$270.15 +7.47 (+2.84%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$270.56 +0.41 (+0.15%)
As of 06/18/2026 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines EPS Results

Actual EPS
$0.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BeOne Medicines Revenue Results

Actual Revenue
$1.51 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BeOne Medicines Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BeOne Medicines Earnings Headlines

BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 1,949 Shares of Stock
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analyst Lance Ippolito says the real opportunity is elsewhere. He's identified 5 dirt-cheap stocks at the forefront of this mega-IPO, including a space ticker that Goldman Sachs, BlackRock, and Morgan Stanley are all buying, a rare resource miner Elon's entire empire depends on, and the chip supplier Starlink satellites can't function without. Access his free SpaceX Investing Blackbook before IPO day arrives.tc pixel
See More BeOne Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email.

About BeOne Medicines

BeOne Medicines (NASDAQ:ONC) Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

View BeOne Medicines Profile